Promising results for Roche 

After a December announcement that Roche's Tecentrig, Avastin and chemo together had cut patients' risk of cancer worsening and death, they have just released more survival data.

Roche has revealed that in a phase 3 trial, the two meds, combined with chemo, had beaten out an Avastin-chemo combo at prolonging lung cancer patients' lives.

The trial, focused on previously untreated non-small-cell lung cancer patients, showed that the survival benefit extended across various subgroups, and it was seen in patients with tumors expressing varying levels of PD-L1.

Click here to view the entire article.